Analysts Viewpoint Alnylam Pharmaceuticals Inc [ALNY] Records 50-Day SMA of $149.27 Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Analysts Viewpoint Alnylam Pharmaceuticals Inc (ALNY) Becoming More Attractive for Investors In a filing, Alnylam Pharmaceuticals Inc revealed its Director SHARP PHILLIP A unloaded Company’s shares for reported $4.54 million on
Analysts Viewpoint Goldman downgrades Alnylam Pharmaceuticals Inc (ALNY) rating to a Neutral Alnylam Pharmaceuticals Inc’s recent filing unveils that its Director SHARP PHILLIP A unloaded Company’s shares for reported $4.54 million on
Analysts Viewpoint Alnylam Pharmaceuticals Inc (ALNY) Becoming More Attractive for Investors In a filing, Alnylam Pharmaceuticals Inc revealed its Director SHARP PHILLIP A unloaded Company’s shares for reported $4.54 million on